# Fangyuan Capital

Fangyuan Capital is a Private Equity based in Hong Kong, Hong Kong.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Hong Kong, Hong Kong
- **Region:** Asia
- **Address:** 香港中環夏愨道12號美國銀行中心503-505室
- **Founded:** 2008
- **Assets under management:** Undisclosed
- **Website:** www.fangyuanfh.com

## Regulatory record

- **Reports private funds:** No

## About

Fangyuan Capital (Hong Kong) Limited is a private equity firm based in Hong Kong, Hong Kong SAR - China. It focuses on venture capital investments. The firm manages approximately $181 million in assets, with $25.16 million in available capital.

## Sectors

- Healthcare Services
- Financials
- Real Estate
- Energy Transition & Renewables
- Technology

## Offices

- Singapore

## People

- 刘骞 (Chad Liu) — 董事长 (Chairman)
- 邓体顺 (Thomas Deng) — 副董事长 (Vice Chairman)
- 马琳琳 (Linlin Ma) — 副董事长/联席首席投资官 (Vice Chairman/Co-CIO)
- 张智斌 (Zhibin Zhang) — 副董事长/联席首席投资官 (Vice Chairman/Co-CIO)
- 谭姝玥 (Sophia Tan) — 副董事长/方圆基金联席行政总裁 (Vice Chairman/Co-CEO of Fangyuan Fund)
- 陈文丰 (Matthew Chan) — 方圆基金联席行政总裁 (Co-CEO of Fangyuan Fund)
- 郑娟 (Christine Zheng) — 方圆资本董事长 (Chairman of Fangyuan Capital)
- 梅文静 (Wenjing Mei) — 方圆资本总裁 (President of Fangyuan Capital)

## Questions

### Who runs investment decisions at Fangyuan Capital?

The group deploys a co-chief investment officer structure. Linlin Ma and Zhibin Zhang serve jointly as Co-CIOs at the parent level, with both having direct trading and research backgrounds spanning Deutsche Bank and Chinese brokerages. Their credit fund and private-equity units each carry separate executive teams, with Sophia Tan and Matthew Chan as co-CEOs of the Fangyuan Fund and Christine Zheng as chairman of Fangyuan Capital.

### How does Fangyuan source proprietary deal flow?

Fangyuan's fixed-income team leans on decades of sell-side and buy-side relationships across Asian credit desks — Chad Liu's background in dollar high-yield and Thomas Deng's former Goldman Sachs strategy role feed primary-issue access. On the private-equity side, Fangyuan Capital structures biomedical fund-of-funds and single-project vehicles, implying manager-selection and co-investment networks in life sciences rather than purely direct origination.

### Does Fangyuan participate in fund commitments or only direct deals?

It does both. Its credit strategy makes direct secondary-market investments in bonds, convertibles, and derivatives, while the private-equity arm runs two biomedical fund-of-funds alongside single-project vehicles — meaning it both commits to external managers and conducts direct healthcare and life-sciences investments.

### Which sectors does Fangyuan Capital explicitly avoid?

No negative screening policy is published. Observed allocations — Asian credit, biomedical fund-of-funds, and life-science single-project vehicles — imply it currently avoids sectors such as consumer tech, industrial manufacturing, and hard infrastructure, though this reflects investment choices rather than a stated exclusion.

## Related profiles

- [Fang Fund Partners](https://altss.com/profile/fang-fund-partners)
- [Fannin Innovation Studio](https://altss.com/profile/fannin-innovation-studio)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/fangyuan-capital-hong-kong-limited

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology